Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andrographis paniculata extract plus favipiravir in mild to moderate COVID-19
TCTR20210609001Phase 3Completed
- Sponsor
- Chulabhorn Royal Academy
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of andrographis paniculata extract, favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Chulabhorn Royal Academy. Started Jun 2021; status: completed.
02
Drugs
andrographis paniculata extractfavipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210609001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210609001.